Conrad Matthew B, Leatherwood Jessica L, Paris Brittany L, George James M, Martinez Rafael E, Vergara-Hernandez Fernando B, Nielsen Brian D, Colbath Aimee C, Arnold Carolyn E, Glass Kati G, Welsh Thomas H, Bradbery Amanda N
Department of Animal and Range Sciences, Montana State University, Bozeman, MT 59717, USA.
Department of Animal Science, Tarleton State University, Stephenville, TX 76402, USA.
J Anim Sci. 2025 Jan 4;103. doi: 10.1093/jas/skaf132.
Extra-label bisphosphonate (BP) use in juvenile horses is anecdotally reported, primarily for analgesic effects, despite the limited scientific understanding of biologic impacts on skeletally immature horses undergoing exercise. The objective of this study was to determine the effects of clodronate disodium (CD), a form of BP, on endocrine regulators of calcium. Thus, 32 yearling Quarter Horses were stratified by age (500 ± 13 d), body weight (BW; 336 ± 26 kg), sex (n = 16 geldings, n = 16 fillies), and initial bone optical density into 1 of 4 treatment groups for a 168-d trial. The experimental period was divided into 2 exercise phases to model industry standards. Investigators were blinded to treatment, and all horses received iso-volumetric intramuscular injections of either 1.8 mg/kg BW CD (OSPHOS) or saline (placebo) on days 0, 42, 84, and 126. Treatments consisted of control (CON; n = 8), 1-dose (1X; n = 8; day 84), 2-dose (2X; n = 8; day 0, 84), and 4-dose groups (4X; n = 8; days 0, 42, 84, 126). Serum samples were collected, and physical measurements were recorded including BW, wither height, hip height, body length, and heart girth circumference (HG) every 42 d, prior to treatment administration. Serum samples were analyzed for growth hormone (GH), calcitonin, parathyroid hormone (PTH), and ionized calcium (Ca2+). Data were analyzed using MIXED and CORR procedures of SAS. All physical measurements increased over time (P ≤ 0.01) but were not affected by treatment (P ≥ 0.62). Similarly, there was no effect of treatment for GH (P = 0.44), but concentrations tended to decrease over time (P = 0.09). A treatment × day interaction was observed for PTH (P = 0.05) where concentrations increased following a second CD dose. Specifically, concentrations increased on day 84 in 4X and on day 126 in 2X following the second treatment with CD whereas 1X and CON remained unchanged. Despite the increase in PTH, there was no effect on calcitonin (P ≥ 0.33). Ionized calcium concentrations decreased over time (P < 0.01) with no effect of treatment (P = 0.26). Parathyroid hormone was negatively correlated with serum Ca2+ (r = -0.28, P < 0.01), whereas calcitonin was not correlated with serum Ca2+ (r = 0.06, P = 0.48) nor PTH (r = -0.13, P = 0.12). According to these results, CD has no effect on growth morphometrics, but its use transiently increases PTH concentrations after 2 doses.
尽管对双膦酸盐(BP)对进行运动的骨骼未成熟马匹的生物学影响的科学认识有限,但据传闻,在幼年马匹中存在超适应症使用BP的情况,主要是为了镇痛效果。本研究的目的是确定氯膦酸二钠(CD,一种BP形式)对钙内分泌调节因子的影响。因此,32匹一岁的美国夸特马按年龄(500±13天)、体重(BW;336±26千克)、性别(n = 16匹阉马,n = 16匹小母马)和初始骨光学密度分层,分为4个治疗组之一,进行为期168天的试验。实验期分为2个运动阶段以模拟行业标准。研究人员对治疗情况不知情,所有马匹在第0、42、84和126天接受等体积的肌肉注射,注射剂量为1.8毫克/千克体重的CD(OSPHOS)或生理盐水(安慰剂)。治疗组包括对照组(CON;n = 8)、单剂量组(1X;n = 8;第84天)、双剂量组(2X;n = 8;第0、84天)和四剂量组(4X;n = 8;第0、42、84、126天)。每42天在给药前采集血清样本,并记录身体测量数据,包括体重、肩高、臀高、体长和胸围(HG)。分析血清样本中的生长激素(GH)、降钙素、甲状旁腺激素(PTH)和离子钙(Ca2+)。使用SAS的MIXED和CORR程序分析数据。所有身体测量数据随时间增加(P≤0.01),但不受治疗影响(P≥0.62)。同样,治疗对GH没有影响(P = 0.44),但其浓度随时间有下降趋势(P = 0.09)。观察到PTH存在治疗×天数的交互作用(P = 0.05),即第二次注射CD后浓度升高。具体而言,在第二次注射CD后,4X组在第84天浓度升高,2X组在第126天浓度升高,而1X组和CON组保持不变。尽管PTH升高,但对降钙素没有影响(P≥0.33)。离子钙浓度随时间下降(P<0.01),不受治疗影响(P = 0.26)。甲状旁腺激素与血清Ca2+呈负相关(r = -0.28,P<0.01),而降钙素与血清Ca2+(r = 0.06,P = 0.48)和PTH(r = -0.13,P = 0.12)均无相关性。根据这些结果,CD对生长形态学指标没有影响,但其使用在2次给药后会短暂升高PTH浓度。